Short Interest in BR Biopharma, Inc. (NASDAQ:BRBI) Grows By 50.9%

BR Biopharma, Inc. (NASDAQ:BRBI) was the target of a significant increase in short interest in August. As of August 14th, there was short interest totaling 3,543 shares, an increase of 50.9% from the July 30th total of 2,348 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 742 shares, the short-interest ratio is currently 4.8 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised BR Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

BR Biopharma Stock Performance

BRBI stock traded up $0.83 during midday trading on Tuesday, reaching $10.75. 107 shares of the company’s stock traded hands, compared to its average volume of 958. The firm has a fifty day simple moving average of $10.84. BR Biopharma has a 52 week low of $9.09 and a 52 week high of $67.01. The firm has a market capitalization of $126.96 million and a P/E ratio of 133.81.

BR Biopharma (NASDAQ:BRBI) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.09 earnings per share for the quarter. The business had revenue of $25.13 million during the quarter.

BR Biopharma Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 4th. Investors of record on Monday, August 17th will be issued a $0.1415 dividend. This represents a $0.57 dividend on an annualized basis and a dividend yield of 5.3%. The ex-dividend date is Monday, August 17th. BR Biopharma’s dividend payout ratio is currently 625.00%.

Hedge Funds Weigh In On BR Biopharma

An institutional investor recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC bought a new stake in BR Biopharma, Inc. (NASDAQ:BRBI) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma makes up approximately 3.2% of Acuitas Investments LLC’s investment portfolio, making the stock its 7th biggest position.

About BR Biopharma

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.